(A) Plasma miRNA levels were assessed by next-generation RNA sequencing and differential analyses performed in (A) women with ACS (cohort 1) and a history of preeclampsia or normotensive (NT) pregnancy (n = 17–18/group), (B) similarly aged women without ACS (cohort 2) and a history of PE versus NT pregnancy (n = 20/group), and (C) women with versus without ACS (cohort 1 vs. cohort 2; n = 35–40/group). Graphs in panels (A–C) show the distribution of miRNAs (dots) according to unadjusted P-values, magnitude of fold change between exposure groups, and plasma level (expressed as the mean counts per million mapped reads, CPM). MiRNAs with P < 0.05 are color-coded green or red to denote decreased or increased plasma level, respectively. Specific P values for each miRNA are provided in Supplementary Tables S1–S3. Heatmaps in panels (A–C) show details on the number of miRNAs according to specific intervals of fold change or mean CPM for all detected miRNAs (total), and subsets of differentially altered miRNAs based on different statistical thresholds of P < 0.05 or FDR < 0.05.